Mabwell Bioscience’s anti-ST2 monoclonal antibody (mAb) has led to a 40% reduction in annualised severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) In the randomised, ...
Monoclonal antibodies (mAbs) have been used successfully for years as therapeutic agents for different pathologies, e.g., various types of cancer and autoimmune diseases. They have become one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback